| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8789951 | Urologic Oncology: Seminars and Original Investigations | 2018 | 7 Pages |
Abstract
The CRP level after CN can be a predictive factor for OS in patients with mRCC treated with tyrosine kinase inhibitor.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jun M.D., Ph.D., Shinya M.D., Ph.D., Shunsuke M.D., Ph.D., Shogo M.D., Ph.D., Tetsutaro M.D., Ph.D., Hideki M.D., Ph.D., Koji M.D., Ph.D., Masanobu M.D., Ph.D., Akio M.D., Ph.D.,